Continuous Delivery of Ranibizumab Via the Port Delivery System for Proliferative Diabetic Retinopathy-related Vitreous Hemorrhage With Pars Plana Vitrectomy and Limited PRP.

* 1\. No more than 8 eyes with previous PRP can be enrolled. Previous PRP will be excluded once this cap of 8 eyes is met.

* 2\. TRD involving or threatening the macula

* 4\. Neovascular glaucoma and/or anterior segment neovascularization

* 5\. Rhegmatogenous Retinal Detachment (RRD) (current as well as history of). (Previously treated tears with laser/cryo or current intraoperative tears treated with focal endolaser/cryo are allowed per investigator discretion; need for gas or oil are excluded).

* 6\. History of PPV or Scleral Buckle or Treatment of RRD

* 7\. Pregnancy or potential for pregnancy

* 8\. Extensive preretinal fibrosis requiring dissection and need for standard (requiring PRP posterior to equator) endolaser PRP or gas or oil. (If mild fibrosis that is easily dissected then such an eye could be included per investigator's discretion)

1.1.1.1 Prior Ocular Treatment

Study Eye

History of corneal transplant

History of conjunctival surgery in the superotemporal quadrant

Previous intraocular device implantation excluding intraocular lenses

History of glaucoma-filtering surgery, tube shunts, or microinvasive glaucoma surgery

Prior participation in a clinical trial involving intravitreal anti-VEGF agents not approved by the FDA on the day of screening

Intraocular laser therapy including selective laser trabeculoplasty, yttrium aluminum garnet (YAG), prophylactic peripheral iridotomy within 1 year of screening, or YAG capsulotomy within 2 months of screening

Contact lens wear within 1 months of screening

Any prior ocular penetrating trauma or blunt trauma deemded significant by the investigator

History of corneal transplantation, including partial-thickness corneal grafts (e.g., Descemet membrane endothelial keratoplasty, Descemet stripping endothelial keratoplasty)

1.1.1.2 VH Characteristics

Study Eye

VH secondary to causes other than PDR (ie. CRVO, BRVO, trauma, etc)

1.1.1.3 Concurrent Ocular Conditions

Study Eye

Retinal pigment epithelial tear, CNV, geographic atrophy secondary to AMD, macular scarring or ischemia limiting visual acuity to worse than 20/400,

Retinal tears or peripheral retinal breaks on depressed fundus examination

Previous violation of the posterior capsule is also an exclusion criterion unless it occurred as a result of YAG laser posterior capsulotomy in association with prior, posterior chamber intraocular lens implantation

Spherical equivalent of the refractive error demonstrating more than 8 diopters of myopia or evidence of pathologic myopia on depressed fundus examination

Preoperative refractive error that exceeds 8 diopters of myopia, for patients who have undergone prior refractive or cataract surgery

Spherical equivalent of the refractive error demonstrating more than 5 diopters of hyperopia

Preoperative refractive error that exceeds 5 diopters of hyperopia, for patients who have undergone prior refractive or cataract surgery

Uncontrolled ocular hypertension or glaucoma (defined as intraocular pressure \[IOP\] \> 25 mmHg or a cup-to-disc ratio \> 0.8, despite treatment with antiglaucoma medication) and any such condition the investigator determines may require a glaucoma-filtering surgery during a patient's participation in the study

Scleral pathology in the superotemporal quadrant (e.g., scleral thinning or calcification)

Conjunctival pathologies (e.g., pterygium, scarring, thinning, fibrosis) in the superotemporal quadrant

History or presence of severe posterior blepharitis, recurrent chalazia or hordeolum, severe dry eye syndrome, or severe allergic conjunctivitis

Ectropion, entropion, or other impairment of the upper or lower eyelid impacting lid functionality needed to protect the ocular surface from exposure

Trichiasis

Corneal neuropathy

Lagophthalmos or incomplete blink

Active or history of facial nerve palsy/paresis

Aphakia or absence of the posterior capsule

Any concurrent intraocular condition (e.g., cataract, glaucoma, AMD,) that would either require surgical intervention during the study to prevent or treat visual loss that might result from that condition or affect interpretation of study results

Any ocular condition suggestive of corneal disorder

Previous corneal endothelial cell damage, including from blunt or surgical trauma (including complicated cataract surgery resulting in complicated lens placement such as anterior chamber intraocular lens, sulcus intraocular lens, or aphakia)

Any active or history of uveitis (e.g., idiopathic, drug-associated or autoimmune associated)

Active or history of keratitis, scleritis, or endophthalmitis

Active ocular or periocular infection (i.e., conjunctivitis, dacryocystitis)

Active or history of Sjogren's syndrome or keratoconjunctivitis sicca

Active or history of floppy eyelid syndrome

Active or history of chronic eye rubbing

Active thyroid eye disease

1.1.1.4 Concurrent Systemic Conditions

Continuous Delivery of Ranibizumab Via the Port Delivery System for Proliferative Diabetic Retinopathy-related Vitreous Hemorrhage With Pars Plana Vitrectomy and Limited PRP.

What this study is about

Continuous Delivery of Ranibizumab Via the Port Delivery System for Proliferative Diabetic Retinopathy-related Vitreous Hemorrhage With Pars Plana Vitrectomy and Limited PRP.

What this study is about